Artelo Biosciences Inc

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded by James Manley on May 2, 2011 and is headquartered in Solana Beach, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.

SOLANA BEACH, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions today announced that Gregory D. Gorgas, CEO of Artelo Biosciences, will be participating in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York City.

Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SOLANA BEACH, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today reported its financial and operating results for the three months ended June 30, 2024 and provided a business update.

Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update

ART26.12 seeks to address a critical need in painful neuropathies, including chemotherapy-induced peripheral neuropathy for which there is no FDA-approved treatment

Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor

Multiple studies confirm ART12.11's superior advantages as a product candidate for the treatment of anxiety related disorders Multiple studies confirm ART12.11's superior advantages as a product candidate for the treatment of anxiety related disorders

Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium

ART26.12 shows efficacy in breast cancer-induced bone pain and diabetic neuropathy ART26.12 shows efficacy in breast cancer-induced bone pain and diabetic neuropathy

Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society

ART12.11 demonstrates comparable pharmacokinetics compared to Epidiolex® ART12.11 demonstrates comparable pharmacokinetics compared to Epidiolex®

Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24

SOLANA BEACH, Calif., May 13, 2024 (GLOBE NEWSWIRE) --  Artelo Biosciences, Inc.  (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today reported financial and operating results for the three months ended March 31, 2024 and provided a business update.

Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

SOLANA BEACH, Calif., May 10, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced that it will be participating in the 2024 Pharma Partnering Summit being held May 14th – 15th in San Diego, California.

Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th

Provides Further Evidence of Multiple Opportunities for Development of the FABP Inhibitor Platform in Cancer & Other Serious Conditions Provides Further Evidence of Multiple Opportunities for Development of the FABP Inhibitor Platform in Cancer & Other Serious Conditions

Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

SOLANA BEACH, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced that Gregory D. Gorgas, President and Chief Executive Officer of Artelo, will be a featured guest on the Benzinga All Access show.

Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time

Major achievements in 2023 lay the foundation for key upcoming milestones Major achievements in 2023 lay the foundation for key upcoming milestones

Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update

ART26.12 Preclinical Dermatology Research Presented to the Immuno-dermatology Leadership Team at Johnson & Johnson ART26.12 Preclinical Dermatology Research Presented to the Immuno-dermatology Leadership Team at Johnson & Johnson

Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge

SOLANA BEACH, CA / ACCESSWIRE / February 15, 2024 / Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it will be participating in the Winter Wrap-Up MicroCap Rodeo Conference, which will be held virtually Tuesday, February 20th through Friday, February 23rd, 2024. Gregory D.

Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th

SOLANA BEACH, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced new research published in the peer-reviewed Journal of Pain. The research article, titled “Discovery and preclinical evaluation of a novel inhibitor of FABP5, ART26.12, effective in Oxaliplatin-induced Peripheral Neuropathy,” highlights Artelo's pre-clinical asset, ART26.12, and its potential ability to treat and prevent Oxaliplatin-Induced Peripheral Neuropathy (OIPN) in a series of separate studies.

Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy

SOLANA BEACH, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it has selected Worldwide Clinical Trials (“Worldwide”), a global award-winning contract research organization (CRO) therapeutically focused on neuroscience, oncology, rare diseases, and cardiometabolic and inflammatory disease, to support the Company's planned Phase 1 trial with ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor in development for the treatment of chemotherapy-induced peripheral neuropathy (CIPN).

Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12

ART12.11 demonstrated improved bioavailability of CBD in both the fed and fasted states ART12.11 demonstrated improved bioavailability of CBD in both the fed and fasted states

Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany

SOLANA BEACH, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced George Warren, PhD., Principal Scientist at Artelo Biosciences, will be presenting new preclinical data on ART12.11, the Company's proprietary cocrystal of cannabidiol (CBD) and tetremethylpyrazine (TMP), at the 4th Annual Med-Cannabis 2023 conference being held December 4-5, 2023 in Frankfurt, Germany.

Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany

$12.9 Million in Cash and Investments as of September 30, 2023; Runway Expected to Reach Meaningful Development Milestones

Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update

SOLANA BEACH, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced new research published in the peer-reviewed journal Pharmaceuticals. The research article, titled “ Cancer-Cachexia-Induced Human Skeletal Muscle Myotube Degeneration is Prevented via Cannabinoid Receptor 2 Agonism in Vitro ,” highlights the promising protective properties of the Company's clinical asset, ART27.13, in helping prevent muscle degeneration caused by cancer.

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers

SOLANA BEACH, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that the research group working with Steven Laviolette, Ph.D., Scientific Advisor at Artelo Biosciences and Professor in the Schulich School of Medicine at the University of Western Ontario, Canada, will be presenting at Neuroscience 2023. The conference will be hosted by the Society for Neuroscience and held November 11-15, 2023 at the Walter E. Washington Convention Center in Washington, D.C. Neuroscience 2023 is the world's largest source of emerging news on brain science and health, with 25,000 neuroscience researchers and clinicians expected in attendance.

Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023

SOLANA BEACH, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that H.C. Wainwright will be hosting a virtual medical expert webinar on October 11, 2023 at 12:00 p.m. Eastern Time to discuss the current treatment landscape for cancer-related anorexia and cachexia. The webinar will feature challenges and opportunities from a historical perspective and future strategies including Artelo's lead candidate ART27.13 which is being developed as a supportive care therapy for people suffering from anorexia and weight loss associated with cancer. ARTL27.13 is currently undergoing a Phase 2a clinical trial for this potential indication.

Principal Investigator of Artelo's CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and Cachexia

SOLANA BEACH, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that Professor Saoirse O'Sullivan, Artelo's Vice President of Translational Sciences, will be presenting at the 13th Congress of the European Pain Federation (EFIC) being held September 20-22, 2023 at the HUNGEXPO Exhibition Centre in Budapest, Hungary.

Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th

SOLANA BEACH, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced it has completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the manufacturing, preclinical and clinical development plan for ART26.12.

Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12

SOLANA BEACH, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that Myles Osborn, Medicinal Chemist at Artelo Biosciences, will be presenting at the 6th Cannabinoid-Derived Drug Development Summit being held September 11-13, 2023 at the Hilton Boston Back Bay hotel in Boston, MA.

Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th

SOLANA BEACH, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.

News for Artelo Biosciences Inc Stock (ARTL)